Arbutus Biopharma Corporation
$4.6
▼
-0.88%
2026-04-21 05:01:01
www.arbutusbio.com
NMS: ABUS
Explore Arbutus Biopharma Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$899.2 M
Current Price
$4.6
52W High / Low
$5.1 / $2.94
Stock P/E
—
Book Value
$0.4
Dividend Yield
—
ROCE
-30.53%
ROE
-38.52%
Face Value
—
EPS
$-0.17
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
19
Beta
0.74
Debt / Equity
5.47
Current Ratio
15.73
Quick Ratio
15.73
Forward P/E
-25.11
Price / Sales
57.6
Enterprise Value
$723.95 M
EV / EBITDA
-27.13
EV / Revenue
51.41
Rating
Strong Buy
Target Price
$5.16
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Alto Neuroscience, Inc. | $27.33 | — | $885.53 M | — | -38.28% | -41.8% | $28.11 / $2.09 | $4.74 |
| 2. | Sol-Gel Technologies Ltd. | $70 | — | $228.83 M | — | -31.74% | -23.72% | $97.97 / $4.11 | $8.19 |
| 3. | Kymera Therapeutics, Inc. | $88.84 | — | $7.31 B | — | -20.82% | -25.78% | $103 / $24.43 | $19.42 |
| 4. | Ardelyx, Inc. | $6.3 | — | $1.59 B | — | -9.92% | -36.21% | $8.4 / $3.21 | $0.68 |
| 5. | Actinium Pharmaceuticals, Inc. | $1.44 | — | $42.98 M | — | -82.74% | -1.67% | $1.95 / $0.95 | $0.25 |
| 6. | Aditxt, Inc. | $0.35 | — | $0.39 M | — | -318.91% | -6.99% | $2,594.48 / $0.39 | $-151.87 |
| 7. | IO Biotech, Inc. | $0.01 | — | $0.55 M | — | -197.41% | -2.4% | $2.79 / $0.01 | $0.01 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.05 M | 0.53 M | 10.74 M | 1.76 M | 1.57 M | — |
| Operating Profit | -7.64 M | -8.29 M | 1.91 M | -13.03 M | -11.95 M | — |
| Net Profit | -3.76 M | -7.74 M | 2.52 M | -24.53 M | -12.53 M | — |
| EPS in Rs | -0.02 | -0.04 | 0.01 | -0.13 | -0.06 | -0.1 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 14.08 M | 6.17 M | 18.14 M | 39.02 M |
| Operating Profit | -27.05 M | -69.97 M | -78.03 M | -63.22 M |
| Net Profit | -33.5 M | -69.92 M | -72.85 M | -69.46 M |
| EPS in Rs | -0.17 | -0.36 | -0.37 | -0.36 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 94.62 M | 131.71 M | 144.4 M | 195.42 M |
| Total Liabilities | 18.04 M | 34.34 M | 38.38 M | 58.57 M |
| Equity | 76.58 M | 97.37 M | 106.02 M | 136.85 M |
| Current Assets | 94.46 M | 127.32 M | 132.03 M | 151.14 M |
| Current Liabilities | 6.01 M | 15.62 M | 22.49 M | 32.86 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -39.64 M | -64.85 M | -85.94 M | -35.36 M |
| Investing CF | 15.58 M | 22.95 M | 50.77 M | -74.94 M |
| Financing CF | 5.72 M | 52 M | 30.65 M | 31.81 M |
| Free CF | -39.64 M | -65.03 M | -86.94 M | -35.87 M |
| Capex | — | -0.18 M | -1.01 M | -0.51 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -65.98% | -53.51% | — | — |
| Earnings Growth % | 4.02% | -4.89% | — | — |
| Profit Margin % | -1133.04% | -401.57% | -178.01% | — |
| Operating Margin % | -1133.92% | -430.15% | -162.03% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -1108.46% | -391.3% | -158.54% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.